China’s state-owned Sinopharm Group Co., Ltd. (HKG: 1099) has announced a new partnership with Germany’s Fresenius Kabi, enhancing collaboration across various sectors including drug sales, warehousing and distribution, as well as big health, medical care, and wellness. Financial details of the agreement were not disclosed.
This partnership marks a continuation of a relationship that began in 1982, reflecting the long-standing commitment between the two companies to innovate and expand their presence in the healthcare market.- Flcube.com
